These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 36126241

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, FTY720 D2201 Study Group.
    Neurology; 2009 Jan 06; 72(1):73-9. PubMed ID: 19122034
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS, Ou YC, Trotman J, Opat S.
    Expert Rev Clin Pharmacol; 2021 Nov 06; 14(11):1329-1344. PubMed ID: 34491123
    [Abstract] [Full Text] [Related]

  • 28. An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
    Gisleskog PO, Valenzuela B, Scherz T, Burcklen M, Pérez-Ruixo JJ, Poggesi I.
    Clin Pharmacokinet; 2021 Sep 06; 60(9):1227-1237. PubMed ID: 33914286
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN, BG-12 Phase IIb Study Investigators.
    Lancet; 2008 Oct 25; 372(9648):1463-72. PubMed ID: 18970976
    [Abstract] [Full Text] [Related]

  • 32. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
    Hang Y, Hu X, Zhang J, Liu S, Deykin A, Nestorov I.
    J Pharmacokinet Pharmacodyn; 2016 Aug 25; 43(4):371-83. PubMed ID: 27299457
    [Abstract] [Full Text] [Related]

  • 33. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J, ATAMS Study Group.
    Lancet Neurol; 2014 Apr 25; 13(4):353-63. PubMed ID: 24613349
    [Abstract] [Full Text] [Related]

  • 34. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW, TOPIC Study Group.
    Lancet Neurol; 2014 Oct 25; 13(10):977-86. PubMed ID: 25192851
    [Abstract] [Full Text] [Related]

  • 35. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R, Oh J.
    Curr Neurol Neurosci Rep; 2022 Nov 25; 22(11):721-734. PubMed ID: 36301434
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.
    Mult Scler; 2017 May 25; 23(6):818-829. PubMed ID: 27503905
    [Abstract] [Full Text] [Related]

  • 37. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.
    JAMA Neurol; 2016 Sep 01; 73(9):1089-98. PubMed ID: 27380540
    [Abstract] [Full Text] [Related]

  • 38. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Kira JI, Nakahara J, Sazonov DV, Kurosawa T, Tsumiyama I, Willi R, Zalesak M, Pingili R, Häring DA, Ramanathan K, Kieseier BC, Merschhemke M, Su W, Saida T.
    Mult Scler; 2022 Jul 01; 28(8):1229-1238. PubMed ID: 34787005
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.